IGF-1 And MGF
The two most important pro-anabolic GH metabolites
Insulin-like growth factor 1 (IGF-1), which is also known as somatomedin C, is a downstream metabolite of growth hormone. IGF-1 is produced primarily by the liver as an endocrine hormone. The production of IGF-1 peaks during the pubertal growth sport and declines thereafter.
Age is yet not the only parameter that influences the production IGF-1. Dieting and a reduced of carbohydrate intake impair the production of the highly anabolic growth hormone derivate, as well. Scientists call this effect "hepatic growth hormone resistance" (Bielohuby. 2011). Practically speaking, the liver stops producing IGF-1. The consequences can range from a minor reduction in muscle protein synthesis to significant reductions in muscle mass and bone mineral density (Grounds. 2002; Bielohuby. 2010).
The administration of IGF-1 in form of injections or via patches will reverse age- or diet-induced trend towards lower muscle and bone mass.
And there is more: Studies indicate that the administration of pro-anabolic GH derivate IGF-1 can do more than to fill up the lack of IGF-1 on energetically and / or calorically reduced diets. Studies from the University of California, San Francisco, for example, indicate that the administration of IGF-1 will trigger significant and relatively rapid changes in body composition in men with excess abdominal fat.
Bodybuilders and other athletes have known about these beneficial effects for decades. Accordingly, IGF-1 and more recently its muscle specific metabolite MGF-1 are among the most popular supplements for athletes competing in sports that require increased strength, maximal lean and minimal fat mass (Azzazy. 2005; Saugy. 2006).
MGF-1 or mechano-growth factor I, which is also known as IGF-I Ec in humans, is only markedly up-regulated in exercised and damaged muscle. It is thus the "bodybuilding cousin" of IGF-1 which is responsible for the repair and structural growth of muscle cells.
The AgeForce IGF-1 + MGF Patch is the first transdermal patch on the market to make use of the perfect synergy between both of these powerful anabolics. In that it mimics the natural increase of MGF and IGF-1 that occurs after strenuous workouts to maximize the repair and growth processes
In contrast what some people in the hardcore bodybuilding scene claim, IGF-1 and MGF do thus act synergistically, not antagonistically, because they interact with different receptors on the muscle (Yang. 2002).
It is this natural synergy of IGF-1 and it's muscle specific cousin MGF which makes the AgeForce IGF-1 + MGF patch so powerful.
A number of studies have been published that attempt to define the role of IGF-IEb/MGF in muscle repair and survival. In aggregate, results from these studies have suggest that during acute skeletal muscle repair after exercise or injury, MGF and subsequently IGF-1 increase above pretraining levels. As Matheny et al. point out in their 2013 review, ...
"[...] these molecular events correlate with the mitogenic and myogenic differentiation events, respectively, that lead to muscle repair (Error: Reference source not found). The initial wave of IGF-IEb mRNA is posited to be translated and then processed to form two independent peptides: mature IGF-I and an E-peptide (or portion of the E-peptide), which is now referred to as MGF. MGF is then responsible for activating quiescent satellite cells (27), which proliferate to provide a pool of myogenic precursor cells for muscle repair. MGF itself, however, despite promoting proliferation, opposes differentiation of precursor cells. At this point, the levels of IGF-IEb/MGF decline, whereas levels of IGF-IEa increase. Like IGF-IEb, IGF-IEa propeptide is processed to generate mature IGF-I as well as an E-peptide, and it is argued that this increase of IGF-IEa is responsible for myoblast differentiation, presumably through the actions of mature IGF-I" (Matheny. 2013).
The new AgeForce IGF-1 + MGF patch does thus work via the same natural pro-anabolic process that is triggered by exercise. It is thus unwarranted to assume that the use of the patch could increase one's risk of developing cancer.
Furthermore, reviews like the one by Lucio Tentori and Grazia Graziani et al. highlight that the hitherto unproven increase in cancer risk that is so often talked about is – if it even exists – a mere result of the enormous doses that are taken by "chemical athletes". It is thus not surprising that the scientists from the U niversity of Rome “Tor Vergata” were unable to find scientific evidence for an increased cancer risk in subjects who are treated with pharmacological doses of IGF-1 and/or GH even if these agents were used for a long period of time (Tentori. 2007).
The AgeForce IGF-1 + MGF patch is designed to slowly deliver a pharmacological dose of the potent anabolic similar to the one that has been used in numerous scientific studies. A potentially increased cancer risk like the one of "chemical athletes" does therefore not exist.
What does exist, though, are the real world benefits of the bioidentical IGF-1 and MGF that is delivered via the patches right into your bloodstream.
Figure 5: Effects of the interaction between GH, IGF-1, MGF, the lipid metabolism and insulin on adipose tissue,
liver and skeletal muscle (base on a figure from Berryman. 2013).
As previously pointed out, IGF-1 and its muscle specific cousin MGF are the main mediators of all the beneficial effects of "growth hormone", a term which is often used to refer to GH and all of its metabolites, on skeletal muscle. As the illustration in Figure 5 shows, these effects include:
Asignificant increase in fat oxidation,
Pronounced increases in skeletal muscle protein synthesis,
Subsequent increases in muscle mass, and
The conservation and promotion of healthy bones (Tahimic. 2013 | not shown in Figure 5)
While IGF-1 and MGF are muscle and bone builder in its own right. Stacking the IGF-1 +MGF Patch® with our best-selling HGH Power Patch® will allow for even more rapid increases in muscle mass and reductions in fat mass. Effects as they have been observed by Waters, et al. in their 1996 study:
Figure 6: Comparison of changes in body mass with GH, IGF or combined therapy after 6 and 12 weeks (Waters. 1996).
As the data in Figure 6 indicates, the combination of both growth hormone and IGF-1 accelerates the accrual of lean mass and boosts the reduction in body fat in men and women (Waters. 1996).
Azzazy, Hassan ME, Mai MH Mansour, and Robert H. Christenson. "Doping in the recombinant era: strategies and counterstrategies." Clinical Biochemistry 38.11 (2005): 959-965.
Berryman, Darlene E., et al. "The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations." Nature Reviews Endocrinology 9.6 (2013): 346-356.
Bielohuby, Maximilian, et al. "Short‐term exposure to low‐carbohydrate, high‐fat diets induces low bone mineral density and reduces bone formation in rats." Journal of Bone and Mineral Research 25.2 (2010): 275-284.
Bielohuby, Maximilian, et al. "Lack of dietary carbohydrates induces hepatic growth hormone (GH) resistance in rats." Endocrinology 152.5 (2011): 1948-1960.
Grounds, Miranda D. "Reasons for the degeneration of ageing skeletal muscle: a central role for IGF-1 signalling." Biogerontology 3.1-2 (2002): 19-24.
Matheny Jr, Ronald W., Bradley C. Nindl, and Martin L. Adamo. "Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration." Endocrinology 151.3 (2010): 865-875.
McKay, Bryon R., et al. "Co‐expression of IGF‐1 family members with myogenic regulatory factors following acute damaging muscle‐lengthening contractions in humans." The Journal of physiology 586.22 (2008): 5549-5560.
Musarò, Antonio, et al. "IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1." Nature 400.6744 (1999): 581-585.
Rao, Madhu N., et al. "Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance." The Journal of Clinical Endocrinology & Metabolism 95.9 (2010): 4361-4366.
Saugy, M., et al. "Human growth hormone doping in sport." British journal of sports medicine 40.suppl 1 (2006): i35-i39.
Tahimic, Candice GT, Yongmei Wang, and Daniel D. Bikle. "Anabolic effects of IGF-1 signaling on the skeleton." Frontiers in endocrinology 4 (2013).
Tentori, Lucio, and Grazia Graziani. "Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?." Pharmacological research 55.5 (2007): 359-369.
Waters, Debra, et al. "Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting: a randomized, double-blind, placebo-controlled trial." Annals of internal medicine 125.11 (1996): 865-872.
Yang, Shi Yu, and Geoffrey Goldspink. "Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation." FEBS letters 522.1 (2002): 156-160.